GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hemostemix Inc (OTCPK:HMTXF) » Definitions » Short Interest

HMTXF (Hemostemix) Short Interest


View and export this data going back to 2015. Start your Free Trial

What is Hemostemix Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Hemostemix's Short Interest

For the Biotechnology subindustry, Hemostemix's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hemostemix's Short Interest Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hemostemix's Short Interest distribution charts can be found below:

* The bar in red indicates where Hemostemix's Short Interest falls into.


Hemostemix Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hemostemix Inc (OTCPK:HMTXF) » Definitions » Short Interest
Comparable Companies
XCNQ:DOSE TSX:BCT XCNQ:MDMA NEOE:BMND XCNQ:PHRM XCNQ:TELI TSXV:GSD TSXV:TTI TSXV:SBM XCNQ:PREV VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB ALNY ONC BNTX XKRX:068270
Traded in Other Exchanges
2VF0:Germany HEM:Canada
Address
707 - 7th Avenue SouthWest, Suite 1150, Calgary, AB, CAN, T2P 3H6
Website
https://www.hemostemix.com
Hemostemix Inc is a biotechnology company. The company's principal business activity is developing, manufacturing, and commercializing blood-derived cell therapies for medical conditions. The Company's technology is a platform for developing autologous cell therapies to treat vascular diseases. The Company's clinical stage consists of ACP-01, autologous cell therapy for the treatment of critical limb ischemia.